LOGIN  |  REGISTER
Terns Pharmaceuticals
Compass Therapeutics

ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 26, 2023 | Last Trade: US$55.10 0.59 -1.06

BAUDETTE, Minn. / Apr 26, 2023 / Business Wire / ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ Headquarters in New York City as follows:

Date:      Tuesday, May 2, 2023
        
Time:      12:00 p.m. ET
        
Webcast:      Click Here

The webcast will be accessible on demand beginning on May 3, 2023, at 7:00 a.m. ET and archived for 90 days thereafter, via the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB